Current Problems in Cancer
Volume 33, Issue 3 , Pages 142-153 , May 2009

The Current Role of Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination of Appendiceal Tumors

  • John H. Stewart IV, MD, FACS

      Affiliations

    • Assistant Professor of Surgery, Director of the Tumor Immunotherapy Program, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Edward A. Levine, MD, FACS

      Affiliations

    • Professor of Surgery, Chief of Surgical Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Perry Shen, MD, FACS

      Affiliations

    • Associate Professor of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina

References 

  1. McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: A population-based study from the surveillance, epidemiology and end-results program, 1973-98. Cancer. 2002;94:3307–3312
  2. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, et al. Pseudomyxoma peritonei (Long-term patient survival with an aggressive regional approach). Ann Surg. 1994;219:112–119
  3. Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg. 1998;85:1332–1339
  4. Sindelar WF, DeLaney TF, Tochner Z, Thomas GF, Dachoswki LJ, Smith PD, et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms (Phase I study). Arch Surg. 1991;126:318–324
  5. Stewart JH, Shen P, Russell GB, Bradley RF, Hundley JC, Loggie BL, et al. Appendiceal neoplasms with peritoneal dissemination: Outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–634
  6. de Bree E, Koops W, Kroger R, van Ruth S, Witkamp AJ, Zoetmulder FA. Peritoneal carcinomatosis from colorectal or appendiceal origin: Correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86:64–73
  7. Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer. 2008;98:875–880
  8. Ponsky JL. An endoscopic view of mucocele of the appendix. Gastrointest Endosc. 1976;23:42–43
  9. Zanati SA, Martin JA, Baker JP, Streutker CJ, Marcon NE. Colonoscopic diagnosis of mucocele of the appendix. Gastrointest Endosc. 2005;62:452–456
  10. Lee YT, Wu HS, Hung MC, Lin ST, Hwang YS, Huang MH. Ruptured appendiceal cystadenoma presenting as right inguinal hernia in a patient with left colon cancer: A case report and review of literature. BMC Gastroenterol. 2006;6:32
  11. Trivedi AN, Levine EA, Mishra G. Adenocarcinoma of the appendix is rarely detected by colonoscopy. J Gastrointest Surg. 2009;13:668–675
  12. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–731
  13. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg. 2001;88:458–463
  14. Elias D, Laurent S, Antoun S, Duvillard P, Ducreux M, Pocard M, et al. [Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy]. Gastroenterol Clin Biol. 2003;27:407–412
  15. Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): A strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11:393–398
  16. Loungnarath R, Causeret S, Brigand C, Gilly FN, Glehen O. [Pseudomyxoma peritonei: new concept and new therapeutic approach]. Ann Chir. 2005;130:63–69
  17. Moran BJ, Meade B, Murphy E. Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis of colorectal origin: A novel treatment strategy with promising results in selected patients. Colorectal Dis. 2006;8:544–550
  18. Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg. 2006;93:1270–1276
  19. Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, et al. Pseudomyxoma peritonei: Clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526–534
  20. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480–487
  21. Dedrick RL. Interspecies scaling of regional drug delivery. J Pharmacol Sci. 1986;75:1047–1052
  22. Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: Tissue concentration gradients. Am J Physiol. 1985;248:F425–F435
  23. Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46:685–689
  24. Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40:567–572
  25. Israel VK, Jiang C, Muggia FM, Tulpule A, Jeffers S, Leichman L, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: A pharmacokinetic and toxicity study. Cancer Chemother Pharmacol. 1995;37:32–38
  26. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42:4265–4269
  27. Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 1998;83:1251–1261
  28. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–550
  29. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase ii trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group study. J Clin Oncol. 1998;16:2620–2624
  30. Dikomey E, Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol. 1992;61:221–233
  31. Roti Roti JL, Kampinga HH, Malyapa RS, Wright WD, Vander Waal RP, Xu M. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones. 1998;3:245–255
  32. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res. 1980;40:1165–1168
  33. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33
  34. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–3743
  35. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol. 2004;22:3284–3292
  36. Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: An analysis of cell proliferation, apoptosis, and expression of p53, CD44, bcl-2. Arch Pathol Lab Med. 2002;126:837–841
  37. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis (A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”). Am J Surg Pathol. 1995;19:1390–1408
  38. Bradley RF, Stewart JH, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551–559
  39. Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH. Clinically aggressive pseudomyxoma peritonei: A variant of a histologically indolent process. J Surg Oncol. 2004;86:10–15
  40. Culliford AT, Brooks AD, Sharma S, Saltz LB, Schwartz GK, O'Reilly EM, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol. 2001;8:787–795
  41. Marcus EA, Weber TK, Rodriguez-Bigas MA, Driscoll D, Meropol NJ, Petrelli NJ. Prognostic factors affecting survival in patients with colorectal carcinomatosis. Cancer Invest. 1999;17:249–252
  42. Pickhardt PJ, Levy AD, Rohrmann CA, Kende AI. Primary neoplasms of the appendix manifesting as acute appendicitis: CT findings with pathologic comparison. Radiology. 2002;224:775–781
  43. Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Experience with 501 procedures. J Am Coll Surg. 2007;204:943–953
  44. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73
  45. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–162
  46. Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: Analysis of prognostic features. World J Surg. 1999;23:23–29
  47. Levine EA. Problems of success and problems of failure: Recurrent disease after cytoreductive surgery and intraperitoneal chemoperfusion. Ann Surg Oncol. 2004;11:351–353

PII: S0147-0272(09)00028-2

doi: 10.1016/j.currproblcancer.2009.06.002

Current Problems in Cancer
Volume 33, Issue 3 , Pages 142-153 , May 2009

Article Tools